http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#Head http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#assertion http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#provenance http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#pubinfo http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#assertion http://purl.obolibrary.org/obo/DOID_7147 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7147 http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00005 http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association http://www.w3.org/2000/01/rdf-schema#label enbrel is a tumor necrosis factor tnf blocker indicated for the treatment of rheumatoid arthritis ra 1 1 polyarticular juvenile idiopathic arthritis jia in patients aged 2 years or older 1 2 psoriatic arthritis psa 1 3 ankylosing spondylitis as 1 4 plaque psoriasis pso in patients 4 years or older 1 5 enbrel is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis ra enbrel can be initiated in combination with methotrexate mtx or used alone enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis jia in patients ages 2 and older enbrel is indicated for reducing signs and symptoms inhibiting the progression of structural damage of active arthritis and improving physical function in patients with psoriatic arthritis psa enbrel can be used with or without methotrexate enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis as enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00005 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#provenance http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#pubinfo http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#sig http://purl.org/nanopub/x/hasSignature DeZd0/Q1Ly6cBsPWMG80Ci50biGmtxjk3Y931bJLq6vR3G/hYWpJHjTYBj5XGGB9eLHoyniq4huvxhF06BuyNoqsX6NfX5slchZaMpegkxb+dKX/J6SUn9gx5x0YLwncyYjnH3Ib3oG/Dk214Cyi7Xrm+Jbchx1gRE4YJTskUm0= http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo http://purl.org/dc/terms/created 2021-06-12T13:22:47.045+02:00 http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RApgvhy0HxNLPuXym4SKIPvijN6JP4_4UWWgGYY1dkgeo https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs